EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
Hosted on MSN1mon
Study Finds Exenatide Not Beneficial for Parkinson Disease
FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield ... receive extended-release exenatide 2 mg by subcutaneous pen injection once ...
Hosted on MSN1mon
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...
Medscape2d
Short-term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
pharmaphorum2d
AstraZeneca improves diabetes pen to maintain its market share
which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension). The new authorisation has been granted for a single-dose, pre-filled pen device that requires no titration ...
Monthly Prescribing Reference1mon
Study Shows Exenatide Not Beneficial for Patients With Parkinson Disease
Study participants (n=194) were randomly assigned 1:1 to receive subcutaneous exenatide extended-release 2mg or placebo once weekly for 96 weeks. The primary endpoint was the Movement Disorder ...